Description of the medicine: Butorphanol (Butorphanolum)
BUTORFANOL (Butorphanolum) * (-) -17- (Cyclobutylmethyl) -morphinan-3, 14-diol.
Synonyms: Moradol, Moradol, Stadol, Torate, Torbugesic, Torgesic, Torbutrol, Verstadol.
Butorphanol is a potent parenteral analgesic. It belongs to the group of opiate receptor agonist antagonists and is close in this respect to pentazocine and nalbuphine. By the strength of action, the speed of onset of the effect and the duration of action is close to morphine, but effective in lower doses than morphine; a dose of 2 mg butorphanol causes severe analgesia. Compared with morphine, it has a low narcotic potential, less ability to cause physical dependence.
Butorphanol is used mainly for severe pain: in the postoperative period, in cancer patients, with renal colic, severe injuries, etc.
Enter intramuscularly or intravenously. The usual single dose for adults intramuscularly is 2 mg every 4 hours (1 to 4 mg, depending on the intensity of the pain). The usual single dose intravenously is 1 mg (0.5 to 2 mg) every 3 to 4 hours.
In anesthetic practice, they are used for sedation, during surgery and in the postoperative period. For the purpose of sedation, they are administered intramuscularly at a dose of 2 mg 30-60 minutes before surgery. During the operation, it is administered intravenously in a dose of 2–4 mg, if necessary, an additional 2 mg with a total dose of 4–12.5 mg (0.06–0.18 mg / kg). Butorphanol can be used in smaller doses (1 - 2 mg) in the composition of "lytic mixtures" - in combination with diprazine, atropine.
In cancer patients, they are administered intramuscularly in a single dose of 1 to 2 mg and a daily dose of 2 to 24 mg.
When using butorphanol, respiratory depression is approximately the same as when taking morphine (in equivalent doses), drowsiness, dizziness, weakness, sweating, and nausea. There is an increase in pressure in the pulmonary artery and systolic blood pressure, increased heart rate, increased intracranial pressure. Hives may occur.
Butorphanol should be used with great care in case of respiratory failure, traumatic brain injuries, impaired liver and kidney function. Caution should be exercised in patients with high blood pressure.
Do not prescribe the drug to patients under the age of 18 years (due to the lack of sufficient experience in studying the effects of the drug in children and adolescents).
The drug should not be prescribed to patients with physical dependence on drugs.
Release form: in 1 ml ampoules containing 0.002 g (2 mg) of butorphanol tartrate, in a package of 50 pieces.
Storage: subject to storage rules for narcotic analgesics.